KR20070073878A - 아리피프라졸 제조를 위해 유용한 신규 중간체와 신규중간체 및 아리피프라졸 제조 방법 - Google Patents
아리피프라졸 제조를 위해 유용한 신규 중간체와 신규중간체 및 아리피프라졸 제조 방법 Download PDFInfo
- Publication number
- KR20070073878A KR20070073878A KR1020077010187A KR20077010187A KR20070073878A KR 20070073878 A KR20070073878 A KR 20070073878A KR 1020077010187 A KR1020077010187 A KR 1020077010187A KR 20077010187 A KR20077010187 A KR 20077010187A KR 20070073878 A KR20070073878 A KR 20070073878A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- aripiprazole
- solvent
- acid
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims abstract description 35
- 239000000543 intermediate Substances 0.000 title claims abstract description 35
- 229960004372 aripiprazole Drugs 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 27
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- DXEOJRJYNSFSFL-UHFFFAOYSA-N 6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2,3-dihydroinden-1-one Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4C(=O)CCC4=CC=3)CC2)=C1Cl DXEOJRJYNSFSFL-UHFFFAOYSA-N 0.000 claims abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002585 base Substances 0.000 claims description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- 239000003444 phase transfer catalyst Substances 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- 235000011181 potassium carbonates Nutrition 0.000 claims description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 claims description 6
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 claims description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- MQAYPFVXSPHGJM-UHFFFAOYSA-M trimethyl(phenyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)C1=CC=CC=C1 MQAYPFVXSPHGJM-UHFFFAOYSA-M 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 2
- 229940106681 chloroacetic acid Drugs 0.000 claims description 2
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 2
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- MOANRQDXNNXOLW-UHFFFAOYSA-N 6-hydroxyindanone Natural products OC1=CC=C2CCC(=O)C2=C1 MOANRQDXNNXOLW-UHFFFAOYSA-N 0.000 abstract description 9
- -1 2,3-dichlorophenyl Chemical group 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- KJDRSWPQXHESDQ-UHFFFAOYSA-N 1,4-dichlorobutane Chemical compound ClCCCCCl KJDRSWPQXHESDQ-UHFFFAOYSA-N 0.000 description 2
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 2
- ILXHUZNXWKFGHY-UHFFFAOYSA-N 2,3-dihydroinden-1-one;hydrochloride Chemical compound Cl.C1=CC=C2C(=O)CCC2=C1 ILXHUZNXWKFGHY-UHFFFAOYSA-N 0.000 description 2
- GMCKRZZXDSWMTP-UHFFFAOYSA-N 6-(4-bromobutoxy)-2,3-dihydroinden-1-one Chemical compound BrCCCCOC1=CC=C2CCC(=O)C2=C1 GMCKRZZXDSWMTP-UHFFFAOYSA-N 0.000 description 2
- IXYSVHVGZZIRNC-UHFFFAOYSA-N 6-(4-chlorobutoxy)-2,3-dihydroinden-1-one Chemical compound ClCCCCOC1=CC=C2CCC(=O)C2=C1 IXYSVHVGZZIRNC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004188 dichlorophenyl group Chemical group 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- ZZIANJABSBSRBK-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)piperazine;hydrobromide Chemical compound Br.ClC1=CC=CC(N2CCNCC2)=C1Cl ZZIANJABSBSRBK-UHFFFAOYSA-N 0.000 description 1
- CYQFNNSFAGXCEC-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)piperazine;hydrochloride Chemical compound [Cl-].ClC1=CC=CC(N2CC[NH2+]CC2)=C1Cl CYQFNNSFAGXCEC-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000006085 Schmidt reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0235—Nitrogen containing compounds
- B01J31/0239—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Materials Engineering (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (17)
- (i) 염기와 용매 존재 하에서 및 90 내지 110℃ 범위의 온도에서, X가 Cl 또는 Br을 나타내는 하기 식 (12)의 1,4-디할로부탄과 하기 식 (11)의 화합물을 반응시켜 상기 식 (3)의 신규 중간체를 형성하는 단계 및(ii) 염기, 상 전이 촉매 및 용매 존재 하에서 및 80 내지 120℃ 범위의 온도에서, 단계 (i)에서 얻어진 상기 식 3의 신규 화합물과 하기 식 (9)의 화합물을 반응시켜 상기 식 2의 신규 중간체를 얻는 단계를 포함하는 상기 식 1의 아리피프라졸 제조에 유용한 상기 식 (2)의 신규 중간체 제조 방법.
- (i) 염기와 용매 존재 하에서 및 90 내지 110℃ 범위의 온도에서, X가 Cl 또는 Br을 나타내는 상기 식 (12)의 1,4-디할로부탄과 상기 식 (11)의 화합물을 반응시켜 상기 식 (3)의 신규 중간체를 형성하는 단계,(ii) 염기, 상 전이 촉매 및 용매 존재 하에서 및 80 내지 120℃ 범위의 온도에서, 단계 (i)에서 얻어진 상기 식 (3)의 신규 화합물과 상기 식 9의 화합물을 반응시켜 상기 식 2의 신규 중간체를 얻는 단계 및(iii) 산 존재 하에서 및 50 내지 70℃ 온도에서, 결과물인 상기 식 (2)의 신규 화합물과 소듐 아자이드 또는 트리메틸실릴아자이드를 반응시켜 상기 식 (1)의 화합물을 얻고, 바람직하다면 상기 식 (1)의 화합물을 재결정화시키는 단계를 포함하는 상기 식 1의 아리피프라졸 제조를 위한 개선된 제조 방법.
- 제3항 내지 제5항에 있어서, 소듐 하이드라이드, 소듐 메톡사이드, 트리에틸아민, 포타슘 카보네이트, 소듐 바이카보네이트 및 소듐 카보네이트와 같은 염기, 바람직하게는 트리에틸아민, 가장 바람직하게는 포타슘 카보네이트가 단계 (i)에서 사용되는 것인 방법.
- 제3항 내지 제6항에 있어서, 상기 단계 (i)에서 사용되는 용매는 아세톤, 클로로포름, 메틸렌 클로라이드, 에틸렌 디클로라이드, 디메틸 포름아미드, 디메틸술폭사이드, 아세토니트릴 및 그의 등가물로부터 선택되고, 바람직하게는 아세톤 및 가장 바람직하게는 1,4-디할로부탄인 것인 방법.
- 제3항 내지 제7항에 있어서, 상기 단계 (i)에서 사용되는 온도는 90-110℃이고 가장 바람직하게는 100-110℃인 것인 방법.
- 제3항 내지 제8항에 있어서, 상기 단계 (ii)에서 사용되는 염기는 소듐 카보네이트, 포타슘 카보네이트, 소듐 바이카보네이트, 포타슘 바이카보네이트, 소듐 하이드라이드, 포타슘 하이드라이드 및 트리에틸아민을 포함하고, 가장 바람직하게는 소듐 카보네이트인 것인 방법.
- 제3항 내지 제9항에 있어서, 상기 단계 (ii)에서 사용되는 염기는 아세토니트릴, 아세톤, 디메틸 포름아미드, 디메틸 술폭사이드, 에탄올, 메탄올, n-부탄올 및 물로부터 선택되고, 바람직하게는 아세톤과 물, 가장 바람직하게는 물인 것인 방법.
- 제3항 내지 제10항에 있어서, 상기 단계 (ii)에서 사용되는 온도는 80-120℃이고 가장 바람직하게는 100-120℃인 것인 방법.
- 제3항 내지 제11항에 있어서, 상기 단계 (i)과 단계 (ii)에서 사용되는 상기 상 전이 촉매는 테트라 부틸암모늄 클로라이드, 테트라 부틸암모늄 브로마이드, 벤질 트리에틸 암모늄 클로라이드, 페닐트리메틸 암모늄 클로라이드인 것인 방법.
- 제3항 내지 제12항에 있어서, 상기 단계 (iii)에서 사용되는 산은 황산, 알루미늄 클로라이드, 보론 트리플루오로 에테레이트, 트리플루오로 아세트산, 메탄 술폰 산, 클로로아세트 산, 디클로로아세트 산 및 트리플루오로 메탄 술폰산을 포함하고, 바람직하게는 트리플루오로 아세트 산과 메탄 술폰 산이고, 가장 바람직하게는 트리플루오로 아세트 산인 것인 방법.
- 제3항 내지 제13항에 있어서, 상기 단계 (iii)에서 사용되는 반응물인 아자이드는 트리메틸실릴아자이드와 소듐 아자이드이고 바람직하게는 소듐 아자이드인 것인 방법.
- 제3항 내지 제14항에 있어서, 상기 단계 (iii)에서 사용되는 온도는 50 - 90℃이고 가장 바람직하게는 60 - 70℃인 것인 방법.
- 제3항 내지 제15항에 있어서, 상기 단계 (iii)에서 사용되는 소듐 아자이드의 양은 사용된 상기 식 (2)의 화합물에 대하여 1-5 몰 당량이고, 바람직하게는 1.5-4 몰 당량인 것인 방법.
- 제3항 내지 제16항에 있어서, 상기 단계 (iii)에서 재결정화에 사용되는 용매는 아세톤, 클로로포름, 메틸렌 클로라이드, 에틸렌 디클로라이드, 디메틸 포름아미드, 디메틸술폭사이드, 아세토니트릴 및 그 등가물로부터 선택되고, 바람직하게는 아세톤이고, 가장 바람직하게는 메탄올인 것인 방법.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2004/000316 WO2006038220A1 (en) | 2004-10-08 | 2004-10-08 | Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070073878A true KR20070073878A (ko) | 2007-07-10 |
KR101041551B1 KR101041551B1 (ko) | 2011-06-15 |
Family
ID=34959292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077010187A KR101041551B1 (ko) | 2004-10-08 | 2004-10-08 | 아리피프라졸 제조를 위해 유용한 신규 중간체와 신규중간체 및 아리피프라졸 제조 방법 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7872132B2 (ko) |
EP (1) | EP1812395B1 (ko) |
JP (1) | JP4819818B2 (ko) |
KR (1) | KR101041551B1 (ko) |
CN (1) | CN101068789B (ko) |
AT (1) | ATE396178T1 (ko) |
AU (1) | AU2004323810B2 (ko) |
CA (1) | CA2584789C (ko) |
DE (1) | DE602004014041D1 (ko) |
EA (1) | EA012180B1 (ko) |
IL (1) | IL182439A (ko) |
NZ (1) | NZ554731A (ko) |
WO (1) | WO2006038220A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012134206A3 (en) * | 2011-03-31 | 2012-11-29 | Daewoong Pharmaceutical Co., Ltd. | Process for the preparation of anhydrous aripiprazole crystal form ii |
KR20200037320A (ko) * | 2017-08-09 | 2020-04-08 | 론자 리미티드 | 4-(헵타플루오로-2-프로필) 아닐린의 제조 방법 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008026220A1 (en) * | 2006-08-28 | 2008-03-06 | Lupin Limited | A process for purification of 7-(4-bromobutoxy)-3,4 dihydrocarbostyril, an intermediate for manufacture of aripirazole |
RU2497819C2 (ru) | 2007-05-21 | 2013-11-10 | Ривайва Фармасьютикалс, Инк. | Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина |
CN101323590B (zh) * | 2007-06-15 | 2011-07-20 | 成都弘达药业有限公司 | 阿立哌唑的合成方法及其中间体 |
KR101251561B1 (ko) | 2012-08-13 | 2013-04-08 | 주식회사 삼오제약 | 아리피프라졸의 제조에 유용한 신규 중간체, 이의 제조방법 및 이를 이용한 아리피프라졸의 제조 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB850663A (en) | 1956-10-22 | 1960-10-05 | Parke Davis & Co | Substituted piperazines and process for their production |
DE3026331A1 (de) * | 1980-07-11 | 1982-02-18 | Basf Ag, 6700 Ludwigshafen | Indanon-oxyalkyl-piperazinderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitung |
ES8601148A1 (es) * | 1984-12-10 | 1985-11-16 | Ferrer Int | Procedimiento de obtencion de nuevos derivados imidazoliletoxiindanicos. |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
JP4902945B2 (ja) * | 2003-01-09 | 2012-03-21 | 大塚製薬株式会社 | アリピプラゾールの製造法 |
CA2458929C (en) | 2003-01-09 | 2009-09-08 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing aripiprazole |
US20080299216A1 (en) * | 2007-06-01 | 2008-12-04 | Protia, Llc | Deuterium-enriched aripiprazole |
-
2004
- 2004-10-08 KR KR1020077010187A patent/KR101041551B1/ko active IP Right Grant
- 2004-10-08 WO PCT/IN2004/000316 patent/WO2006038220A1/en active IP Right Grant
- 2004-10-08 CA CA2584789A patent/CA2584789C/en not_active Expired - Fee Related
- 2004-10-08 NZ NZ554731A patent/NZ554731A/en not_active IP Right Cessation
- 2004-10-08 AU AU2004323810A patent/AU2004323810B2/en not_active Ceased
- 2004-10-08 DE DE602004014041T patent/DE602004014041D1/de active Active
- 2004-10-08 CN CN2004800445194A patent/CN101068789B/zh not_active Expired - Fee Related
- 2004-10-08 EA EA200700816A patent/EA012180B1/ru not_active IP Right Cessation
- 2004-10-08 EP EP04791863A patent/EP1812395B1/en active Active
- 2004-10-08 US US11/664,849 patent/US7872132B2/en not_active Expired - Fee Related
- 2004-10-08 JP JP2007535326A patent/JP4819818B2/ja not_active Expired - Fee Related
- 2004-10-08 AT AT04791863T patent/ATE396178T1/de not_active IP Right Cessation
-
2007
- 2007-04-10 IL IL182439A patent/IL182439A/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012134206A3 (en) * | 2011-03-31 | 2012-11-29 | Daewoong Pharmaceutical Co., Ltd. | Process for the preparation of anhydrous aripiprazole crystal form ii |
KR101340214B1 (ko) * | 2011-03-31 | 2013-12-10 | 주식회사 대웅제약 | 무수 아리피프라졸 ⅱ형 결정의 제조방법 |
US9000165B2 (en) | 2011-03-31 | 2015-04-07 | Daewoong Pharmaceutical Co., Ltd. | Process for the preparation of anhydrous aripiprazole crystal form II |
KR20200037320A (ko) * | 2017-08-09 | 2020-04-08 | 론자 리미티드 | 4-(헵타플루오로-2-프로필) 아닐린의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
AU2004323810A1 (en) | 2006-04-13 |
DE602004014041D1 (de) | 2008-07-03 |
EA200700816A1 (ru) | 2007-10-26 |
EP1812395A1 (en) | 2007-08-01 |
CA2584789A1 (en) | 2006-04-13 |
ATE396178T1 (de) | 2008-06-15 |
CN101068789B (zh) | 2010-12-15 |
KR101041551B1 (ko) | 2011-06-15 |
CN101068789A (zh) | 2007-11-07 |
JP4819818B2 (ja) | 2011-11-24 |
JP2008515879A (ja) | 2008-05-15 |
NZ554731A (en) | 2009-12-24 |
AU2004323810B2 (en) | 2011-11-17 |
US20090203907A1 (en) | 2009-08-13 |
IL182439A0 (en) | 2007-07-24 |
IL182439A (en) | 2011-04-28 |
EP1812395B1 (en) | 2008-05-21 |
US7872132B2 (en) | 2011-01-18 |
WO2006038220A1 (en) | 2006-04-13 |
CA2584789C (en) | 2010-11-23 |
EA012180B1 (ru) | 2009-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL182439A (en) | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the intermediates and aripiprazole | |
JPH0240066B2 (ko) | ||
US6538134B2 (en) | 4-Benzyl-2-hydroxy-1,4-oxazine-3-one and polymorphic forms thereof | |
KR101146009B1 (ko) | 광학 분리에 의한 활성 피페리딘 화합물의 제조방법 | |
CA2199645C (en) | Methods for the manufacture of quinolone carboxylic acids derivatives and intermediates thereof | |
NO147838B (no) | Mellomprodukt til bruk ved fremstilling av det hypotensive middel 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimetoksykinazolin | |
JP2001521498A (ja) | O−(3−アミノ−2−ヒドロキシ−プロピル)−ヒドロキシミック酸ハロゲン化物の製造方法 | |
US20080058523A1 (en) | Processes for synthesizing piperazine-piperidine compounds | |
JPH06100540A (ja) | 5−イソキノリンスルホン酸アミド誘導体 | |
EP1002798A1 (en) | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative | |
KR890001241B1 (ko) | 4-아세틸 이소퀴놀리논 화합물의 제조방법 | |
JPH04169583A (ja) | フェノチアジン誘導体およびその製造方法 | |
JP4238978B2 (ja) | ベンゾアゼピン化合物及びその製造法 | |
SU999967A3 (ru) | Способ получени 6-N-замещенных 6-амино-3-пиридазинилгидразинов или их солей | |
JP5079809B2 (ja) | (3−アルキル−5−ピペリジン−1−イル−3,3a−ジヒドロ−ピラゾロ[1,5−a]ピリミジン−7−イル)−アミノ誘導体および中間体の合成のための方法および合成のための中間体 | |
JPH08503939A (ja) | α−アリール‐γ‐ブチロラクトンの製造方法 | |
KR20240057365A (ko) | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 개선된 제조방법 | |
JPH02218648A (ja) | プロポキシニトロベンゼン類の製法 | |
JPH0328432B2 (ko) | ||
CS195347B2 (en) | Process for preparing antihypertensive 6,7-dimethoxy4-4-amino-2-/4-/2-furoyl/-1-piperazinyl/quinazoline | |
KR20070090937A (ko) | 2-(피라졸-1-일)피리딘 유도체 | |
CS197312B2 (en) | Method of producing 3,4-dimethoxy-6-/4-/2-furoyl/-1-piperazinyl-thiocarbamido/benzonitrile | |
JPH09241246A (ja) | ジシアノピラジン誘導体及びその製造方法 | |
JP2002114765A (ja) | 3−アミノ−4−カルボニルピラゾール化合物の製造方法 | |
JPH02117630A (ja) | ハロゲン化エチルベンゼンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140508 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150427 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160217 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170208 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180209 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190314 Year of fee payment: 9 |